BlackRock’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-3,082,031
| Closed | -$7.03M | – | 5348 |
|
|
2024
Q2 | $7.03M | Buy |
3,082,031
+2,410,004
| +359% | +$9.21M | ﹤0.01% | 3561 |
|
|
2024
Q1 | $2.9M | Sell |
672,027
-8,637
| -1% | -$30.1K | ﹤0.01% | 3868 |
|
|
2023
Q4 | $2.08M | Sell |
680,664
-439,643
| -39% | -$826K | ﹤0.01% | 4028 |
|
|
2023
Q3 | $1.61M | Sell |
1,120,307
-65,338
| -6% | -$126K | ﹤0.01% | 4080 |
|
|
2023
Q2 | $2.95M | Sell |
1,185,645
-201,253
| -15% | -$550K | ﹤0.01% | 3896 |
|
|
2023
Q1 | $3.72M | Sell |
1,386,898
-105,611
| -7% | -$507K | ﹤0.01% | 3766 |
|
|
2022
Q4 | $8.1M | Sell |
1,492,509
-27,148
| -2% | -$228K | ﹤0.01% | 3490 |
|
|
2022
Q3 | $19M | Buy |
1,519,657
+150,376
| +11% | +$1.72M | ﹤0.01% | 3061 |
|
|
2022
Q2 | $6.76M | Sell |
1,369,281
-1,930,568
| -59% | -$10.7M | ﹤0.01% | 3690 |
|
|
2022
Q1 | $25.1M | Sell |
3,299,849
-10,363
| -0.3% | -$98.3K | ﹤0.01% | 3029 |
|
|
2021
Q4 | $33.8M | Buy |
3,310,212
+68,127
| +2% | +$868K | ﹤0.01% | 2941 |
|
|
2021
Q3 | $43.5M | Buy |
3,242,085
+12,319
| +0.4% | +$201K | ﹤0.01% | 2760 |
|
|
2021
Q2 | $70.9M | Buy |
3,229,766
+80,859
| +3% | +$1.8M | ﹤0.01% | 2468 |
|
|
2021
Q1 | $75.8M | Buy |
3,148,907
+255,314
| +9% | +$5.93M | ﹤0.01% | 2354 |
|
|
2020
Q4 | $52.1M | Buy |
2,893,593
+262,986
| +10% | +$3.93M | ﹤0.01% | 2445 |
|
|
2020
Q3 | $30.4M | Sell |
2,630,607
-53,316
| -2% | -$880K | ﹤0.01% | 2613 |
|
|
2020
Q2 | $65.1M | Buy |
2,683,923
+104,756
| +4% | +$1.73M | ﹤0.01% | 2108 |
|
|
2020
Q1 | $28.4M | Sell |
2,579,167
-1,192
| -0% | -$22.3K | ﹤0.01% | 2414 |
|
|
2019
Q4 | $68.2M | Sell |
2,580,359
-4,556
| -0.2% | -$107K | ﹤0.01% | 2175 |
|
|
2019
Q3 | $58.9M | Buy |
2,584,915
+116,500
| +5% | +$3.67M | ﹤0.01% | 2195 |
|
|
2019
Q2 | $75.7M | Buy |
2,468,415
+530,999
| +27% | +$11.2M | ﹤0.01% | 2084 |
|
|
2019
Q1 | $32.2M | Sell |
1,937,416
-26,298
| -1% | -$499K | ﹤0.01% | 2529 |
|
|
2018
Q4 | $37.6M | Buy |
1,963,714
+126,892
| +7% | +$4.75M | ﹤0.01% | 2396 |
|
|
2018
Q3 | $96M | Buy |
1,836,822
+146,462
| +9% | +$7.99M | ﹤0.01% | 1999 |
|
|
2018
Q2 | $73.5M | Buy |
1,690,360
+409,300
| +32% | +$17.5M | ﹤0.01% | 2130 |
|
|
2018
Q1 | $47.5M | Buy |
1,281,060
+535,615
| +72% | +$14.3M | ﹤0.01% | 2296 |
|
|
2017
Q4 | $14.8M | Buy |
745,445
+396,215
| +113% | +$8.52M | ﹤0.01% | 2936 |
|
|
2017
Q3 | $8.69M | Buy |
349,230
+338,519
| +3,160% | +$6.25M | ﹤0.01% | 3246 |
|
|
2017
Q2 | $187K | Buy |
+10,711
| New | +$187K | ﹤0.01% | 4264 |
|
BlackRock's GTHX Position: Q3 2024 in Review
BlackRock sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 3,082,031 shares — an estimated $7.03M sold.
BlackRock first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $96M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- BlackRock reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- BlackRock sold 3,082,031 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $7.03M.
- BlackRock first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 29 quarters.
- BlackRock's G1 Therapeutics, Inc. Common Stock position peaked at $96M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on BlackRock's 13F filing for Q3 2024, filed 13 Nov 2024.